Companies › Aura Biosciences
2 active drug programs in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| belzupacap sarotalocan Complement 3 inhibitor; intravitreal antibody targeting complement cascade | COMPLEMENT3 | Phase 3 | Choroidal Melanoma | Nov 2027 |
| AU-011 anti-PGLYRP4 antibody-drug conjugate | PGLYRP4 | Phase 2 | Eye Cancer; Non-muscle-invasive Bladder Cancer | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06643884 | AU-011 | Phase 2 | Eye Cancer | Oncology | Nov 2026 |
| NCT05483868 | AU-011 | Phase 1 | Non-muscle-invasive Bladder Cancer | Oncology | Mar 2027 |
| NCT06007690 | belzupacap sarotalocan | Phase 3 | Choroidal Melanoma | Oncology | Nov 2027 |
Cash of $42m on 2026-09-30; operating cash outflow about $119m a year; runway about 4 months at that burn, to Feb 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
Dogwood Therapeutics Atossa Therapeutics Curis Can-Fite BioPharma LeonaBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.